These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 15608694

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
    MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM.
    Cancer Res; 2005 Dec 15; 65(24):11265-70. PubMed ID: 16357130
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL, Earel JK, Griffith TS.
    Cancer Gene Ther; 2006 Jun 15; 13(6):628-32. PubMed ID: 16456549
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D.
    Exp Hematol; 2007 Oct 15; 35(10):1527-37. PubMed ID: 17697742
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G.
    J Cell Physiol; 2005 Nov 15; 205(2):246-52. PubMed ID: 15887227
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, Gross N.
    BMC Cancer; 2006 Aug 24; 6():214. PubMed ID: 16930472
    [Abstract] [Full Text] [Related]

  • 19. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K, Kano Y, Ishii H, Furukawa Y.
    J Cell Physiol; 2005 May 24; 203(2):387-97. PubMed ID: 15515013
    [Abstract] [Full Text] [Related]

  • 20. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
    Vanoosten RL, Moore JM, Ludwig AT, Griffith TS.
    Mol Ther; 2005 Apr 24; 11(4):542-52. PubMed ID: 15771957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.